SLG
AMRI

Stanley-Laman Group’s Albany Molecular Research Inc AMRI Stock Holding History

Stanley-Laman Group’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-35,348
Closed -$702K – 370
2015
Q4 		$702K Buy
35,348
+5,785
+20% +$110K 0.12% 190
2015
Q3 		$515K Buy
29,563
+655
+2% +$13.3K 0.1% 196
2015
Q2 		$585K Buy
+28,908
New +$558K 0.11% 193

Other funds holding AMRI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stanley-Laman Group's AMRI Position: Q1 2016 in Review

Stanley-Laman Group sold out of Albany Molecular Research Inc (AMRI) in Q1 2016, closing a stake of 35,348 shares — an estimated $702K sold.

Stanley-Laman Group first reported a position in AMRI in Q2 2015 and held it in 3 quarters. The position peaked at $702K in Q4 2015. 141 funds tracked by Wall St. Rank hold AMRI as of Q1 2016.

  • Stanley-Laman Group reported no remaining Albany Molecular Research Inc position as of Q1 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 35,348 Albany Molecular Research Inc shares in Q1 2016, an estimated $702K.
  • Stanley-Laman Group first reported a position in Albany Molecular Research Inc in Q2 2015 and held it in 3 quarters.
  • Stanley-Laman Group's Albany Molecular Research Inc position peaked at $702K in Q4 2015.
  • 141 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2016.

Based on Stanley-Laman Group's 13F filing for Q1 2016, filed 9 May 2016.